Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of CPI-0209 + Carboplatin in Recurrent Ovarian Cancer
NCT05942300Phase 1Recruiting
- Start
- Jan 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tulmimetostat in ovarian cancer (2 arms). Primary endpoint: Maximum Tolerated Dose at 24 months. Started Jan 2024; status: recruiting.
02
Drugs
tulmimetostat
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05942300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942300.